We are pleased to inform that our subsidiary Company, M/s Deccan Remedies Limited, has received approval from Drug Control Administration, Government of Andhra Pradesh granting License ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gennex Laboratories' subsidiary, Deccan Remedies Limited, has received a drug manufacturing license (Form 25, License No.31/VP/AP/2014/B/R/CC) from the Drug Control Administration, Government of Andhra Pradesh. The license is valid until 28.05.2028 and covers 42 pharmaceutical products for both domestic sale and export purposes. The approved list includes widely-used drugs such as Pantoprazole Sodium, Atorvastatin Calcium, Apixaban, Dolutegravir Sodium, Montelukast Sodium, Pregabalin, Tenofovir Disoproxil Fumarate, and Moxifloxacin Hydrochloride, across multiple pharmacopoeial standards (IP, USP, Ph.Eur, BP, JP). The approval has been built up through multiple incremental endorsements between 2023 and July 2025.
This regulatory clearance significantly expands Deccan Remedies' manufacturing portfolio, enabling it to produce and sell a broad range of high-demand generic APIs and formulations in Indian and overseas markets. The expansion supports potential revenue growth for the subsidiary and is a positive operational development for Gennex Laboratories shareholders.